<DOC>
	<DOC>NCT01763918</DOC>
	<brief_summary>The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH).</brief_summary>
	<brief_title>Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male or female ≥ 18 to ≤ 80 years of age Diagnosis of heterozygous familial hypercholesterolemia On a stable dose of an approved statin and lipid regulating medication Fasting LDLC ≥ 100 mg/dL (2.6 mmol/L) Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) Homozygous familial hypercholesterolemia LDL or plasma apheresis New York Heart Association (NYHA) III or IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes, poorly controlled type 2 diabetes Uncontrolled hypothyroidism or hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia</keyword>
</DOC>